Clinical Trials Logo

Veno-occlusive Disease clinical trials

View clinical trials related to Veno-occlusive Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02338440 Active, not recruiting - Child Clinical Trials

Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT

Start date: January 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Veno-occlusive disease (VOD) after hematopoietic stem cell transplantation (HSCT) remains the major complication. VOD occurs in 11-31% of pediatric HSCT and the mortality reaches up to 50%. Prostaglandin E1 (PGE1) have been reported to prevent and relieve the severity of VOD by Gluckman et al.. Lipo-PGE1 is a transporter of PGE1, which is superior in concentrating PGE1 and acts for prolonged time. Because of the prolonged effective time, lipo-PGE1 acts comparable effects by 1/4~1/8 of PGE1 dose. Empirically, pediatric HSCT centers adopt lipo-PGE1 in dose of 1 mcg/kg/day (0.042 mcg/kg/hr), which is 1/7 of the dose recommended by Gluckman, et al. This prospective study will investigate the concentration of lipo-PGE1 with preventive lipo-PGE1 with empirical dose (1 mcg/kg/day).